

## dextromethorphan-quinidine (NUEDEXTA)

### Diagnoses Considered for Coverage:

- Pseudobulbar affect (PBA)

### Coverage Criteria:

#### 1. For diagnosis of pseudobulbar affect (PBA), approve if:

- Dose does not exceed 2 capsules per day, **and**
- Secondary to one of the following neurologic conditions:
  - a. Amyotrophic Lateral Sclerosis (ALS)
  - b. Alzheimer's disease
  - c. Multiple Sclerosis
  - d. Parkinson's disease
  - e. Stroke
  - f. Traumatic brain injury

### Coverage Duration: one year

#### References:

1. Prescribing Information. Nuedexta. Avanir Pharmaceuticals Inc. 12.2022
2. Ahmed, A, Simmons, Z. Pseudobulbar affect: prevalence and management. Ther Clin Risk Manag. 2013; 9; 483-89.

Effective Date: 8/30/2023